Literature DB >> 24534408

Obesity in pediatric ALL survivors: a meta-analysis.

Fang Fang Zhang1, Michael J Kelly, Edward Saltzman, Aviva Must, Susan B Roberts, Susan K Parsons.   

Abstract

BACKGROUND AND
OBJECTIVE: Previous studies of survivors of pediatric acute lymphoblastic leukemia (ALL) have drawn heterogeneous conclusions regarding the prevalence of obesity and risk factors for developing obesity in pediatric ALL survivors. We sought to determine the prevalence of obesity in pediatric ALL survivors and examine risk factors for obesity through a systematic review and meta-analysis.
METHODS: A MEDLINE search was performed from its inception through 2013. Studies met the inclusion criteria if they (1) included at least 10 survivors of pediatric ALL; (2) assessed the prevalence or indicators of obesity; and (3) compared obesity among ALL survivors to a reference population or external control group. Extracted data included patient and treatment characteristics, study design, population used for comparison, and prevalence of obesity.
RESULTS: Forty-seven studies met the inclusion criteria. Despite significant heterogeneity among the studies (I(2) = 96%), the mean BMI z score in 1742 pediatric ALL survivors was 0.83 (95% confidence interval: 0.60-1.06), which corresponds to the 80th BMI percentile, indicating a significantly higher BMI in pediatric ALL survivors than the reference population. Subgroup analyses found a high prevalence of obesity in ALL survivors regardless of survivors' receipt of cranial irradiation, gender, or age at diagnosis.
CONCLUSIONS: Obesity is prevalent in pediatric ALL survivors and is independent of patient- and treatment-related characteristics. Clinicians need to screen for obesity and its associated health conditions early in survivorship.

Entities:  

Keywords:  acute lymphoblastic leukemia; obesity; pediatric; survivors

Mesh:

Year:  2014        PMID: 24534408      PMCID: PMC3934345          DOI: 10.1542/peds.2013-3332

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  63 in total

1.  Bone mineral density, body composition, and height in long-term survivors of acute lymphoblastic leukemia in childhood.

Authors:  I M van der Sluis; M M van den Heuvel-Eibrink; K Hählen; E P Krenning; S M de Muinck Keizer-Schrama
Journal:  Med Pediatr Oncol       Date:  2000-10

2.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

3.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  J Clin Epidemiol       Date:  2009-07-23       Impact factor: 6.437

4.  Screening survivors of childhood acute lymphoblastic leukemia for obesity, metabolic syndrome, and insulin resistance.

Authors:  Hasan Karakurt; Nazan Sarper; Suar Çakı Kılıç; Sema Aylan Gelen; Emine Zengin
Journal:  Pediatr Hematol Oncol       Date:  2012-09       Impact factor: 1.969

5.  Energy expenditure, energy intake and prevalence of obesity after therapy for acute lymphoblastic leukemia during childhood.

Authors:  E I Mayer; M Reuter; R E Dopfer; M B Ranke
Journal:  Horm Res       Date:  2000

6.  Body composition in children in remission from acute lymphoblastic leukemia.

Authors:  Alexia J Murphy; Jonathan C K Wells; Jane E Williams; Mary S Fewtrell; Peter S W Davies; David K Webb
Journal:  Am J Clin Nutr       Date:  2006-01       Impact factor: 7.045

7.  Risk factors for excess weight gain in children treated for acute lymphoblastic leukaemia.

Authors:  J J Reilly; J C Ventham; J Newell; T Aitchison; W H Wallace; B E Gibson
Journal:  Int J Obes Relat Metab Disord       Date:  2000-11

8.  Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004.

Authors:  Dianne Pulte; Adam Gondos; Hermann Brenner
Journal:  J Natl Cancer Inst       Date:  2008-09-09       Impact factor: 13.506

9.  Early indicators of dysmetabolic syndrome in young survivors of acute lymphoblastic leukemia in childhood as a target for preventing disease.

Authors:  Georgios Trimis; Maria Moschovi; Ioannis Papassotiriou; George Chrousos; Fotini Tzortzatou-Stathopoulou
Journal:  J Pediatr Hematol Oncol       Date:  2007-05       Impact factor: 1.289

10.  Body composition, muscle strength deficits and mobility limitations in adult survivors of childhood acute lymphoblastic leukemia.

Authors:  Kirsten K Ness; K Scott Baker; Donald R Dengel; Nancy Youngren; Shalamar Sibley; Ann C Mertens; James G Gurney
Journal:  Pediatr Blood Cancer       Date:  2007-12       Impact factor: 3.838

View more
  38 in total

1.  Survivors of standard risk acute lymphoblastic leukemia do not have increased risk for overweight and obesity compared to non-cancer peers: a report from the Children's Oncology Group.

Authors:  Susan J Lindemulder; Linda C Stork; Bruce Bostrom; Xiaomin Lu; Meenakshi Devidas; Stephen Hunger; Joseph P Neglia; Nina S Kadan-Lottick
Journal:  Pediatr Blood Cancer       Date:  2015-02-07       Impact factor: 3.167

2.  Associating Physical Activity Levels with Motor Performance and Physical Function in Childhood Survivors of Acute Lymphoblastic Leukemia.

Authors:  Stanley H Hung; Anne Rankin; Naznin Virji-Babul; Sheila Pritchard; Christopher Fryer; Kristin L Campbell
Journal:  Physiother Can       Date:  2017       Impact factor: 1.037

3.  Clinical impact of sedentary behaviors in adult survivors of acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort study.

Authors:  Carrie R Howell; Carmen L Wilson; Matthew J Ehrhardt; Robyn E Partin; Sue C Kaste; Jennifer Q Lanctot; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson; Kirsten K Ness
Journal:  Cancer       Date:  2017-12-04       Impact factor: 6.860

4.  Gut microbial composition difference between pediatric ALL survivors and siblings.

Authors:  Ronay Thomas; Wendy S W Wong; Reem Saadon; Thierry Vilboux; John Deeken; John Niederhuber; Suchitra K Hourigan; Elizabeth Yang
Journal:  Pediatr Hematol Oncol       Date:  2020-05-19       Impact factor: 1.969

5.  Prevalence and Predictors of Overweight and Obesity Among a Multiethnic Population of Pediatric Acute Lymphoblastic Leukemia Survivors: A Cross-Sectional Assessment.

Authors:  Austin L Brown; Philip J Lupo; Heather E Danysh; Mehmet F Okcu; Michael E Scheurer; Kala Y Kamdar
Journal:  J Pediatr Hematol Oncol       Date:  2016-08       Impact factor: 1.289

Review 6.  Obesity in Childhood Cancer Survivors: Call for Early Weight Management.

Authors:  Fang Fang Zhang; Susan K Parsons
Journal:  Adv Nutr       Date:  2015-09-15       Impact factor: 8.701

7.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report.

Authors:  Saro H Armenian; Wassim Chemaitilly; Marcus Chen; Eric J Chow; Christine N Duncan; Lee W Jones; Michael A Pulsipher; Alan T Remaley; Alicia Rovo; Nina Salooja; Minoo Battiwalla
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-30       Impact factor: 5.742

8.  Changes in body mass index, height, and weight in children during and after therapy for acute lymphoblastic leukemia.

Authors:  Emily K Browne; Yinmei Zhou; Wassim Chemaitilly; John C Panetta; Kirsten K Ness; Sue C Kaste; Cheng Cheng; Mary V Relling; Ching-Hon Pui; Hiroto Inaba
Journal:  Cancer       Date:  2018-10-25       Impact factor: 6.860

9.  Food craving and obesity in survivors of pediatric ALL and lymphoma.

Authors:  Marissa Shams-White; Michael J Kelly; Cheryl Gilhooly; Shanshan Liu; Aviva Must; Susan K Parsons; Edward Saltzman; Fang Fang Zhang
Journal:  Appetite       Date:  2015-08-30       Impact factor: 3.868

10.  Effect of Sex on Biomarker Response in a Mouse Model of the Hematopoietic Acute Radiation Syndrome.

Authors:  Jace W Jones; Jenna Alloush; Rajendran Sellamuthu; Hui Lin Chua; Thomas J MacVittie; Christie M Orschell; Maureen A Kane
Journal:  Health Phys       Date:  2019-04       Impact factor: 1.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.